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society and the MoH. Indirect costs were in all cases higher than
direct costs.
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OBJECTIVES: To determine the impact of publication bias on
the magnitude of the treatment effect in clinical studies evaluat-
ing hormone therapy (HT) on the frequency of hot ﬂashes among
menopausal women. METHODS: We searched computerized
databases for English language articles from 1966 to April, 2004.
Two reviewers evaluated 5840 published titles, identiﬁed
placebo-controlled observations that met explicit inclusion cri-
teria, and extracted data pertaining to study characteristics,
interventions used, and outcomes measured. Studies evaluating
the effects of HT in cancer patients were excluded. The impact
of HT on the frequency of hot ﬂashes was calculated using a
random-effects model. The effects of publication bias were
assessed using the trim and ﬁll method. RESULTS: Based on our
criteria, a total of 29 studies were included in the meta-analysis.
A funnel plot examining the presence of publication bias was
asymmetric, suggesting that small non-signiﬁcant studies were
missing. The trim and ﬁll method suggested that four studies
were missing. The standardized mean difference between 
unadjusted and adjusted point estimates was 0.8 (CI 0.3–1.2).
CONCLUSIONS: When evaluating the efﬁcacy and safety of
therapeutic interventions, the validity of ﬁndings from a meta-
analysis is questionable if publication bias is present. Given that
restricting a meta-analysis to published literature can distort the
effects under investigation by as much as 30%, researchers
should try to detect and correct for publication bias when syn-
thesizing the evidence. Our meta-analysis conﬁrmed that HT is
effective in relieving menopause-related hot ﬂashes but less than
originally suggested. For therapies with signiﬁcant risk-beneﬁt
tradeoffs, the clinical decision could vary upon a complete and
unbiased assessment.
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OBJECTIVES: To determine the magnitude of the placebo effect
in studies examining the impact of hormone therapy (HT) on 
the frequency of hot ﬂashes among menopausal women. We 
also examined the inﬂuence of data type on point estimates.
METHODS: We searched computerized databases for English
language articles from 1966 to April, 2004. Two reviewers eval-
uated 5840 published titles, identiﬁed placebo-controlled obser-
vations that met explicit inclusion criteria, and extracted data
pertaining to study characteristics, interventions used, and out-
comes measured. Studies evaluating the effects of HT in cancer
patients were excluded. The magnitude of the placebo effect on
frequency of hot ﬂashes was calculated using a random-effects
model. The effects of outcome type (binary and continuous) were
assessed separately. RESULTS: Based on our criteria, a total of
25 studies were included in the meta-analysis. When the effects
of data type were assessed, studies with continuous outcomes (N
= 18) reported a larger placebo effect than studies using binary
outcomes (N = 7). The difference in standardized mean differ-
ence (SMD) = 2.52 (CI: 2.17–2.8). A larger placebo effect was
observed in weekly hot ﬂashes. The difference between weekly
and daily SMD = 0.5 (CI: 0.15–0.85). CONCLUSIONS: Place-
bos are used to control for natural remission and provide a stan-
dard for comparison to active treatment. However, it is difﬁcult
to distinguish a true placebo effect from reporting bias when
studying hot ﬂashes; patients tend to please investigators by
reporting positive changes when no improvement took place.
Overall, we found a greater placebo effect in studies with con-
tinuous outcomes possibly due to the systematic differences in
the self-recording of symptoms or the natural decline of symp-
toms. These ﬁndings may apply to other patient reported out-
comes in other conditions.
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OBJECTIVES: This study uses conjoint analysis to examine
women’s health preferences toward three post-menopausal risk
factors: osteoporosis, heart disease, and breast cancer. Willing-
ness to pay (WTP) to reduce the risk of exposure was also exam-
ined. METHODS: A questionnaire containing three parts:
conjoint analysis to assess health preferences toward the easiest
(hardest) condition to live with (levels: 25%, 50%, 75%), WTP
to reduce risk factor exposure 0%, 50%, 25%, respectively, and
demographic characteristics was administered to a random
sample of women currently participating in a large observational
study at the University of Alabama Birmingham, School of 
Medicine. Of the 99 responses obtained, 83 were suitable for
conjoint analysis. Visual analog scales established validity and
quality of life measures assessed current health status. RESULTS:
Overall utilities for the best possible preferences were 1.573, 
-0.696, -0.877 for osteoporosis, heart disease, and breast
cancer, respectively, with Log likelihood = -1077.21, X2 = 671.4, 
P < 0.001, Pseudo R = 0.24 for the binary logit model. Similar
patterns were observed for the worst possible preferences.
Average WTP values to reduce exposure to the three risk factors
levels that were the easiest to live with ranged from $224.50 to
$3500. Alternatively, WTP values to reduce exposure for risk
factor levels that were the hardest to live with ranged from
$425.00 to $6500. Patient preferences were consistent with the
assumptions of decision theory and income levels. CONCLU-
SIONS: Findings from this study reveal the usefulness of con-
joint analysis to assess health preferences with respect to disease
severity, risk, and the possibility of future encounters.
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OBJECTIVE: To examine antibiotic prescribing and outcomes
in outpatient treatment of community-acquired pneumonia in
non-elderly adults. METHODS: We analyzed claims from eight
managed care organizations. Index claims were outpatient or
